HIV drug resistance lasts about one year in women treated with nevirapine to prevent infant infection

Feb 16, 2010

A new international study reported in PLoS Medicine confirms that a single dose of nevirapine (sdNVP) can lead to HIV treatment failure in women who receive the drug to prevent transmission of the AIDS virus to their infants. However, the increased risk of failure could only be detected in women who began full HIV treatment within about a year after receiving sdNVP.

Because of its convenience and availability, sdNVP has become the mainstay for preventing mother-to-child transmission (MTCT) of in many developing country settings. However, previous studies have shown that sdNVP can induce nevirapine-resistant HIV in treated mothers, potentially increasing the chance that subsequent HIV therapy containing , or other drugs of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, will fail.

In the current study, Jeffrey S.A. Stringer of the University of Alabama at the Birmingham Centre for Infectious Disease Research in Zambia and colleagues enrolled 355 nevirapine-exposed and 523 nevirapine-unexposed women at two sites in Zambia, one site in Kenya, and two sites in Thailand and followed them for 48 weeks after starting (ART). They found that prior exposure to sdNVP was associated with an increased risk of subsequent ART failure, but that this risk was largely confined to women with a more recent exposure. sdNVP-exposed women in whom this interval was more than 12 months had essentially the same prevalence of failure at 48 weeks as women without prior exposure. The researchers conclude that women requiring ART within 12 months of sdNVP exposure should not be prescribed ART that includes nevirapine or efavirenz.

These findings suggest that, provided NNRTI-containing ART is not given to HIV-positive women within a year of nevirapine exposure, single-dose nevirapine can be safely used to prevent MTCT without substantially compromising the mother's future antiretroviral treatment options. The authors point out that liberalizing the criteria for starting full ART in pregnant women would ensure that most women receiving sdNVP would not need ART for at least a year. In the occasional circumstance where a woman did need therapy soon after single-dose NVP exposure, a protease inhibitor-containing regimen or a triple nucleoside regimen could be prescribed.

Explore further: Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum

More information: Stringer JSA, McConnell MS, Kiarie J, Bolu O, Anekthananon T, et al. (2010) Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine: A Multi-country, Prospective Cohort Study. PLoS Med 7(2): e1000233. doi:10.1371/journal.pmed.1000233

add to favorites email to friend print save as pdf

Related Stories

Breastfeeding now safer for infants of HIV-infected mothers

Feb 04, 2008

An antiretroviral drug already in widespread use in the developing world to prevent the transmission of HIV from infected mothers to their newborns during childbirth has also been found to substantially cut the risk of subsequent ...

Antenatal HIV

Nov 22, 2007

South Africa's Prevention of Mother to Child Transmission (PMTCT) Programme has severe shortcomings that could be doing more harm than good. HIV patients are missing out on opportunities to receive a key intervention namely ...

Recommended for you

HIV+ women respond well to HPV vaccine

Apr 16, 2014

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. The study's findings ...

User comments : 0

More news stories

Researchers discover target for treating dengue fever

Two recent papers by a University of Colorado School of Medicine researcher and colleagues may help scientists develop treatments or vaccines for Dengue fever, West Nile virus, Yellow fever, Japanese encephalitis and other ...

Study recalculates costs of combination vaccines

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Hackathon team's GoogolPlex gives Siri extra powers

(Phys.org) —Four freshmen at the University of Pennsylvania have taken Apple's personal assistant Siri to behave as a graduate-level executive assistant which, when asked, is capable of adjusting the temperature ...

Better thermal-imaging lens from waste sulfur

Sulfur left over from refining fossil fuels can be transformed into cheap, lightweight, plastic lenses for infrared devices, including night-vision goggles, a University of Arizona-led international team ...

Deadly human pathogen Cryptococcus fully sequenced

Within each strand of DNA lies the blueprint for building an organism, along with the keys to its evolution and survival. These genetic instructions can give valuable insight into why pathogens like Cryptococcus ne ...